Krro-110 receives orphan drug designation from u.s. fda for alpha-1 antitrypsin deficiency

Cambridge, mass., march 14, 2025 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing rna for both rare and highly prevalent diseases, announced today that the u.s. food and drug administration (fda) has granted orphan drug designation to the investigational medicine krro-110 for the treatment of alpha-1 antitrypsin deficiency (aatd).
KRRO Ratings Summary
KRRO Quant Ranking